Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2022 | $23.00 → $17.00 | Strong Buy | Raymond James |
| 9/14/2021 | $14.00 | Market Outperform | JMP Securities |
| 7/30/2021 | $24.00 | Overweight | Cantor Fitzgerald |
-SEC Filing
After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID Levels Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Impact Payer Costs Approximately 250 Patients of a Planned Total of 600 Subjects Currently Enrolled in SHIELD II Unblinded Interim Analysis to be Conducted Once Approximately 400 PatientsComplete Their 30-Day Follow-up; Top-line Results Expected in the First Quarter of 2025
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates PolyPid (NASDAQ:PYPD) with a Buy and maintains $14 price target.
PETACH TIKVA, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 13, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a questi
Approximately 320 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up, Which is Expected in Fourth Quarter of 2024; Top-Line Results Anticipated in First Quarter of 2025 Recent Successful Financing of Up to $14 Million Extends Company's Cash Runway into Second Quarter of 2025, Beyond the Anticipated Timing for SHIELD II Top-line Results, Assuming Warrants are Fully Exercised Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 14, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:
PETACH TIKVA, Israel, July 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 14, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question
PETACH TIKVA, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's management will participate in investor meetings at the Craig-Hallum 15th Annual Alpha Select Conference on November 19, 2024, in New York, NY. Investors interested in meeting with PolyPid should contact the conference representative directly. About PolyPid PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encap
PETACH TIKVA, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 13, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a questi
SHIELD I Study is One of the Largest Phase 3 Trials in the Prevention of SSIs in Colorectal Resection Conducted in Over a Decade Pre-Specified and Post-Hoc Analyses Suggested that D-PLEX100 May Benefit Patients with Increased SSI Risk, Including Those with Lengthy Incisions SHIELD II Study, the Ongoing Second Phase 3 with D-PLEX100, Focuses on Patients with Large Surgical Incisions; Top-line Results Expected in Q1 2025 PETACH TIKVA, Israel, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced a publication in the International Journal of Surgery (IJS) titled, "Effec
SC 13G/A - PolyPid Ltd. (0001611842) (Subject)
SC 13G/A - PolyPid Ltd. (0001611842) (Subject)
SC 13G/A - PolyPid Ltd. (0001611842) (Subject)
Raymond James reiterated coverage of PolyPid with a rating of Strong Buy and set a new price target of $17.00 from $23.00 previously
JMP Securities initiated coverage of PolyPid with a rating of Market Outperform and set a new price target of $14.00
Cantor Fitzgerald initiated coverage of PolyPid Ltd. with a rating of Overweight and set a new price target of $24.00
PETACH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors, effective November 6, 2023, following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a biopharmaceutical industry veteran with extensive executive business development, clinical, and R&D expertise. She is an experienced sector investor and was a practicing physician for nearly 15 years. "We are thrilled to welcome Dr. Tweezer-Zaks to the PolyPid Board. She has had a distinguished career as a practicing physic
Dr. Berger Brings Extensive Expertise in Deep Brain Tumor Treatment The Company Expects to Initiate a Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors by the end of 2022 PETAH TIKVA, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Mitchel S. Berger, M.D., to its Oncology Advisory Board. Dr. Berger is the Berthold and Belle N. Guggenhime Professor of the Department of Neurological Surgery at the University of California, San Francisco (U
PETAH TIKVA, Israel, Jan. 03, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that its Board of Directors has appointed Dikla Czaczkes Akselbrad, currently the Company's Executive Vice President and Chief Financial Officer, as PolyPid's Chief Executive Officer, effective July 1, 2022. Amir Weisberg, who currently serves as Chief Executive Officer and a director, will direct a transition period with Ms. Czaczkes Akselbrad beginning on April 1, 2022, and will retire from the Chief
6-K - PolyPid Ltd. (0001611842) (Filer)
EFFECT - PolyPid Ltd. (0001611842) (Filer)
F-3 - PolyPid Ltd. (0001611842) (Filer)